Learn more about clinical trials at this NCCN Member Institution.
The mission of the Fred & Pamela Buffett Cancer Center is to coordinate basic and clinical cancer research, patient care and educational programs and to facilitate the application of new knowledge about the diagnosis, treatment and prevention of cancer.
The Fred & Pamela Buffett Cancer Center is a National Cancer Institute (NCI) designated cancer center at the University of Nebraska Medical Center. The Cancer Center was initially established in 1983, and is one of 64 NCI-designated cancer centers in the country. The Fred & Pamela Buffett Cancer Center incorporates the expertise and resources from each of the Colleges and Institutes that comprise the University of Nebraska Medical Center and its affiliated hospital The Nebraska Medical Center. Patients across the United States and around the world visit the Fred & Pamela Buffett Cancer Center to receive innovative treatment from some of the top specialists in the world.
In 2012, the U.S. News & World Report ranked The Nebraska Medical Center as one of America’s Best Hospitals for cancer treatment. Additionally, The Nebraska Medical Center is the first hospital in Nebraska to receive the Blue Distinction Center for Complex and Rare Cancers from Blue Cross and Blue Shield of Nebraska. Only 88 other medical centers in the United States have earned the same distinction. Blue Distinction Centers for Complex and Rare Cancers were developed in strategic collaboration with the National Comprehensive Cancer Network (NCCN) and input from a panel of leading clinicians and professional organizations.
Considered to be a Center of Excellence for the study of lymphoma, much emphasis is placed on integrated laboratory and clinical research in this disease. The Center's Lymphoma Study Group has reviewed more than 40,000 biopsies and created a clinical outcome database to correlate the findings. The Nebraska Medical Center stem cell transplantation program has been ranked as one of the busiest adult and pediatric stem cell transplantation programs in the world. The program, which was established in 1983, has been recognized internationally for pioneering autologous transplantation for lymphoma, using peripheral stem cells as an alternative rescue product; conducting ground-breaking transplant studies; and performing transplants in alternate settings other than traditional inpatient hospital units.
The Fred & Pamela Buffett Cancer Center has a $5.3 million National Cancer Institute Specialized Program of Research Excellence (SPORE) grant in pancreatic cancer. SPORE grants are large, multidisciplinary federal grants that fund scientific research aimed at bringing new laboratory findings quickly to the clinic. Additionally, the recent recruitment of nationally recognized breast cancer researchers along with a strong nucleus of established breast cancer researchers at UNMC, enabled the Cancer Center to create a Center for Breast Cancer Research that will transform the breast cancer research program at the Fred & Pamela Buffett Cancer Center into a world-class research program for breast cancer detection, prevention, and treatment.
The Fred & Pamela Buffett Cancer Center's research efforts are organized into four main research programs which facilitate inter-collaborative research initiatives among members through participation in program activities and focus group meetings. The existing programs are organized to foster collaboration between basic science and clinical researchers. The Fred & Pamela Buffett Cancer Center research programs are as follows:
Cancer Genes and Molecular Regulation Program (CGMRP) - Members in this program study the mechanisms that cause cells to become malignant and form tumors.
Molecular Biochemical Etiology Program (MBEP) - Researchers in this program stimulate collaborative multidisciplinary research to further our understanding of the molecular and biochemical events leading to oncogenesis and to develop strategies for abrogating these events.
Lymphoma Research Program (LRP) - Research in this program is focused on identifying causes, evaluation of molecular markers of prognosis, and development of new therapies for lymphomas.
Cancer Prevention and Control Program (CPCP) - Members in this developing program focus on improving the current knowledge base for promoting overall reductions in cancer incidence, morbidity, and mortality, as well as conducting research on reducing cancer risk and incidence, reducing complications secondary to cancer, managing symptoms and improving quality of life and survivorship.